Reduced Expression of Cyclooxygenase-2 in Primary Breast Cancer by Boneberg, Eva-Maria et al.
1042 Correspondence | JNCI Vol. 100, Issue 14  |  July 16, 2008
 CORRESPONDENCE 
 Reduced Expression of 
Cyclooxygenase-2 in 
Primary Breast Cancer 
 Recently reported results of a phase 2 study 
combining the aromatase inactivator 
exemestane with the cyclooxygenase-2 
(COX-2) inhibitor celecoxib for the treat-
ment of breast cancer showed that patients 
receiving the combined treatment had 
response rates and clinical benefit rates that 
were similar to those of the group receiving 
exemestane only (1). The rationale for 
using a COX-2 inhibitor for the treatment 
of breast cancer is based on several reports 
that COX-2 is frequently overexpressed in 
breast cancer ( 2 ) and that elevated levels of 
COX-2 in breast cancer specimens were 
associated with tumor progression and poor 
prognosis ( 3 ). The disappointing effect of 
celecoxib in this clinical study indicates that 
COX-2 may not be as crucial for the pro-
gression of human breast cancer as previ-
ously hypothesized. A possible explanation 
for the unexpected findings could be that 
the reported overexpression of COX-2 in 
human breast cancer was not correct. In 
one previous study, only the tumor samples 
were analyzed, and the expression of COX-
2 was correlated with clinical parameters 
such as disease-free survival or lymph node 
metastasis without comparison to healthy 
tissue ( 3 ). In studies that compared COX-2 
expression in tumor and healthy tissues, 
COX-2 expression was mainly analyzed 
by immunohistochemistry ( 4 – 6 ). These 
immunhistochemical methods, however, 
were not quantitative and would strongly 
depend on the quality of the antibody and 
the staining protocol and also on the selec-
tion of the analyzed region. Only a few 
studies analyzed the expression of COX-2 
by reverse transcription – polymerase chain 
reaction (RT – PCR) ( 4 – 6 ), but measure-
ments with conventional RT – PCR are also 
not quantitative. Recent real-time RT –
 PCR analyses ( 7 ) used just one housekeep-
ing gene for normalization, which could 
lead to incorrect interpretations because 
the expression levels of housekeeping genes 
can vary considerably between tumor tis-
sues and healthy tissues. 
 To quantitatively measure the expres-
sion of COX-2 in breast cancer tissues, 
tumor-adjacent tissues, and healthy breast 
tissues, we performed real-time RT – PCR 
analysis and normalized the expression of 
COX-2 to the mean expression of four dif-
ferent housekeeping genes. The expression 
of COX-2 mRNA was decreased in the 
breast cancer samples (mean COX-2 expres-
sion: 0.3, 95% conﬁ dence interval [CI] = 0.2 
to 0.4) in comparison with tumor-adjacent 
tissues (mean expression: 2.0, 95% CI = 1.3 
to 2.7) and healthy tissues (mean expression: 
1.0, 95% CI = 0.5 to 1.4) ( Figure 1 ). The 
median expression of COX-2 in tumor tis-
sues was only 20% of the median expression 
in  healthy tissues ( P < .001) and only 10% 
of that of tumor-adjacent tissues ( P < .001). 
Furthermore, none of the tumor samples 
with relative high COX-2 expression 
exceeded the range of COX-2 expression 
found in healthy tissue samples or tumor-
adjacent samples. Some tumor samples 
showed only about 1% of the mRNA levels 
measured in tumor-adjacent tissues. 
 Our results indicate that COX-2 is 
expressed at reduced levels in human breast 
cancer, not overexpressed as previously 
reported. Furthermore, we did not ﬁ nd any 
correlation of COX-2 mRNA expression in 
the tumor tissues with the mRNA expres-
sion of HER2/neu, estrogen receptor alpha, 
or the progesterone receptor (data not 
shown). The loss of COX-2 expression in 
established breast cancers that we observed 
could explain the failure of celecoxib to 
inhibit tumor growth in the cited clinical 
trial ( 1 ). 
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Switzerland). Expression proﬁ les of COX-2 and several other cancer-related genes of 48 breast 
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the expression of housekeeping genes, the expression of COX-2 was normalized to the mean 
expression of four housekeeping genes ( GAPDH ,  UBC ,  TBP , and  B2M ). Relative expression was 
calculated with the    Ct method. The  horizontal line indicates the median relative expression of 
each group. *** P < .001 vs tumor adjacent tissues,  +++ P < .001 vs healthy breast tissues.  P values 
(two-sided) were calculated using the Mann – Whitney test. 
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